This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Response to rivastigmine transdermal patch or memantine plus rivastigmine patch is affected by apolipoprotein E genotype in Alzheimer patients


Han, Hyun Jeong, Kim, Byeong C., Lee, Jun-Young, Ryu, Seung-Ho, Na, Hae-Ri, Yoon, Soo Jin, Park, Hyun Young, Shin, Joon Hyun, Cho, Soo-Jin, Yi, Hyon Ah, Choi, Mun Seong, Heo, Jae-Hyeok, Park, Kyung Won, Kim, Kwang K., Choi, Seong Hye


Dementia And Geriatric Cognitive Disorders, Volume: 34, No.: 3-4, Pages.: 167-173

Year of Publication



Background/aims: The apolipoprotein E (APOE) genotype in response to pharmacological treatments in patients with Alzheimer’s disease (AD) remains a matter of controversy. This analysis investigated the effect of the APOE genotype on the clinical response to rivastigmine transdermal patch monotherapy or memantine plus rivastigmine patch in patients with mild to moderate AD.; Methods: Two hundred and six (n = 206) patients with probable AD and Mini-Mental State Examination (MMSE) scores of 10-20 were randomized to rivastigmine patch monotherapy or memantine plus rivastigmine patch for 24 weeks. Of the 206 patients with probable AD, 146 patients who consented to genetic testing for APOE were included and assessed for this subgroup study.; Results: There were no significant differences on MMSE, NPI, ADAS-cog, ADCS-ADL, CDR-SB, NPI and FAB between rivastigmine patch monotherapy and memantine plus rivastigmine patch according to the APOE genotype. However, patients with moderately severe AD (MMSE ≤15) who were APOE ε4 carriers showed higher responder rates on ADCS-ADL with memantine plus rivastigmine patch compared to rivastigmine patch monotherapy.; Conclusion: Moderately severe AD patients with the APOE ε4 allele may respond more favorably to memantine plus rivastigmine patch than ε4 noncarriers.; Copyright © 2012 S. Karger AG, Basel.

Bibtex Citation

@article{Han_2012, doi = {10.1159/000342927}, url = {}, year = 2012, publisher = {S. Karger {AG}}, volume = {34}, number = {3-4}, pages = {167--173}, author = {Hyun Jeong Han and Byeong C. Kim and Jun-Young Lee and Seung-Ho Ryu and Hae Ri Na and Soo Jin Yoon and Hyun Young Park and Joon Hyun Shin and Soo-Jin Cho and Hyon-Ah Yi and Mun Seong Choi and Jae-Hyeok Heo and Kyung Won Park and Kwang K. Kim and Seong Hye Choi}, title = {Response to Rivastigmine Transdermal Patch or Memantine plus Rivastigmine Patch is affected by Apolipoprotein E Genotype in Alzheimer Patients}, journal = {Dementia and Geriatric Cognitive Disorders} }


activities of daily living, aged, aged, 80 and over, alzheimer disease, analysis of variance, apolipoproteins e, cholinesterase inhibitors, drug therapy, drug therapy combination, female, genetics, genotype, humans, male, memantine, middle aged, phenylcarbamates, prospective studies, rivastigmine, therapeutic use, transdermal patch

Types of Dementia

Alzheimer’s Disease

Types of Study

Randomised Controlled Trial

Type of Outcomes

Behaviour, Cognition

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime